摘要:
An oral composition containing, as essential components, (i) at least one member selected from the group consisting of hydroxamic acids having the formula (I) and the salts thereof: R - CH₂ - CO - NHOH .......... (I)
wherein R represents an alkyl group or an alkoxyphenyl group and (ii) at least one member selected from the group consisting of proteins, peptides, amino acids and the salts thereof as an astringent inhibitor. This oral composition can effectively inhibit particular astringency caused by hydrohexamic acids or the salts thereof and has good foaming properties and a pleasant feeling upon application.
摘要:
A hair cosmetic composition comprising a cationic polymeric material and a cyclodextrin. This hair cosmetic composition has an excellent perm odor inhibition effect and a high persistence of the inhibition effect.
摘要:
The present invention relates to a crosslinking inhibitor which inhibits the formation of crosslinking (aged crosslinking) of collagen by utilizing the Maillard reaction between collagen and sugar. The inhibitor comprises a silicon compound having at least one silanol group in its molecule, such as methyl silanetriol, dimethyl silanediol, trimethyl silanol, dodecyl silanetriol, cycrohexyl silanetriol or propenyl silanetriol.
摘要:
A detergent composition containing an α-sulfo fatty acid alkyl ester salt and a fragrance composition, wherein the amount of the α-sulfo fatty acid alkyl ester salt is from 1 to 30% by mass relative to the total mass of the detergent composition, the fragrance composition contains a fragrance (A) described below, and the amount of the fragrance (A) is from 0.07 to 0.5% by mass relative to the total mass of the detergent composition. Fragrance (A): a fragrance composed of at least one fragrance component selected from the group consisting of dihydromyrcenol, isobornyl acetate, α-hexyl cinnamic aldehyde, lilial, tetrahydrolinalool, amyl salicylate, verdox, vertenex, tricyclodecenyl acetate, tricyclodecenyl propionate, Iso E Super and habanolide.
摘要:
This liquid detergent contains an α-sulfofatty acid ester salt (component (a)), an alkylbenzene sulfonate (component (b)), a polyoxyethylene alkyl ether sulfate (component (c)), and an alkanolamine (component (d)). The amount of the component (a) is 5% by mass or greater; the total amount of the component (b) and the component (c) is 5% by mass or greater; the total amount of the component (a), the component (b), and the component (c) is 10% by mass to 50% by mass, the mass ratio represented by (d)/(a) is 1/5 or greater, and the mass ratio represented by (a)/((b) + (c)) is 1 or less.
摘要:
It is an object of the present invention to provide a marker substance capable of accurately determining a risk of developing metabolic syndrome in vivo. That is, the present invention provides the followings: a marker peptide for determining the risk of developing the metabolic syndrome; an antibody or an aptamer bound to the marker peptide for determining the risk of developing the metabolic syndrome; a microarray in which the antibody or the aptamer bound to the marker peptide for determining the risk of developing the metabolic syndrome has been immobilized on a carrier; a method for determining the risk of developing the metabolic syndrome, comprising measuring an amount or the presence or absence of the marker peptide for determining the risk of developing the metabolic syndrome in a biological sample collected from a subject; and a kit for determining the risk of developing the metabolic syndrome, comprising the antibody or the aptamer or comprising the microarray.
摘要:
A composition, including: (A) Panax notoginseng ; and at least one of (B) a Piper longum extract and (C) vitamin B1, a salt thereof or a derivative thereof.
摘要:
A composition including: at least one mixture selected from the group consisting of a mixture of (A) panaxatriol and (B) protopanaxatriol and a mixture of (C) panaxadiol and (D) protopanaxadiol, wherein a ratio (A)/(B) of a mass of the (A) panaxatriol to a mass of the (B) protopanaxatriol is 1 or greater, and a ratio (C)/(D) of a mass of the (C) panaxadiol to a mass of the (D) protopanaxadiol is 1 or greater.